Previous 10 | Next 10 |
This has been an absolutely dismal year for growth stocks. The Vanguard Growth ETF has fallen about 33% over the past 12 months. While times have been tough for most growth stocks, shares of TransMedics Group (NASDAQ: TMDX) have more than tripled in 2022. Investors reacted to expl...
Summary CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability a...
TransMedics Group, Inc. (TMDX) Q3 2022 Results Conference Call November 03, 2022 04:30 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Allen Gong - J.P....
TransMedics Group ( NASDAQ: TMDX ) is trading ~20% higher after the company posted better-than-expected Q3 result and forecast revenues above estimates, helped by higher sales of OCS Heart and OCS Liver. Revenue rose 378.6% Y/Y to $25.7M, and be...
TransMedics Group press release ( NASDAQ: TMDX ): Q3 GAAP EPS of -$0.25 beats by $0.15 . Revenue of $25.7M (+378.6% Y/Y) beats by $6.82M . 2022 Financial Outlook: TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85...
TransMedics Reports Third Quarter 2022 Financial Results PR Newswire Net revenue of $25.7 million , comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $ 80 million to $85 mil...
Summary We advocate that TransMedics Group remains a speculative buy in the current market rout. Profitability and earnings trends continue to push north and serve as solid fundamental momentum looking ahead. Shares are trading above historical multiples, however, this enables...
TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022 PR Newswire ANDOVER, Mass. , Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ trans...
Summary TransMedics is a long-term revenue growth story in organ transplant procedures. The company’s technology is seeing smooth adoption replacing the current standard of care. Long-term investors can buy the company’s shares around the current price. ...
TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference PR Newswire ANDOVER, Mass. , Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming ...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...